Inovio Biomedical Announces Initiation Of HIV Clinical Trial For DNA Vaccine Delivered Using Electroporation

Inovio Biomedical Corporation (NYSE Amex: INO), a leader in DNA vaccine design, development and delivery, and the HIV Vaccine Trials Network (HVTN) announced today the initiation of a phase I clinical study of Inovio’s PENNVAX™-B preventive DNA vaccine delivered using its proprietary electroporation technology. The multi-center study will be conducted at several HVTN clinical sites under a protocol designated HVTN-080.

Source: Inovio Biomedical Announces Initiation Of HIV Clinical Trial For DNA Vaccine Delivered Using Electroporation